Ocular Therapeutix Seeking FDA Approval for ReSure Sealant

Ocular Therapeutix is in pursuit of FDA premarket approval for its ReSure Sealant, a hydorgel-based sealant designed to protect the eye after undergoing cataract surgery, according to a Fierce Drug Delivery report.

Advertisement

ReSure Sealant is a polymer and hyrogel-based substance that is created to prevent leaks from surgical incisions in the cornea. The sealant will naturally dissolve and be removed from the eye by tears.

ReSure Sealant is the first ophthalmic sealant of its kind that will be considered for FDA approval.

More Articles on Ophthalmology:
AJL Ophthalmic Develops New Material for Bioimplants
U.S. Patent & Trademark Office Grants OptiMedica Fundamental Patent
Lahey Hospital & Medical Center Acquires Essex VitreoRetinal Services

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.